TWM524707U - Embedded particle using Hericium erinaceus mycelial to embed lactic acid bacteria - Google Patents

Description

An embedded particle of lactic acid bacteria embedded in hyphae of Hericium erinaceus

The invention relates to an embedded granule of a lactic acid bacteria, in particular to an embedded granule of a lactic acid bacteria embedded in a hyphae of the genus Hericium.

Lactic acid bacteria are a kind of probiotics, and generally refer to bacteria that use carbohydrates to ferment and produce a large amount of lactic acid. Lactobacillus is a primary health-care strain. Functionally, it prevents the invasion of pathogens by adhering to the intestinal tract of the host, and has positive effects on the host. The current product types on the market are liquid, powder or hard capsules. Among them, since the product type of lactic acid bacteria will affect its efficacy, it plays an important part in development and production.

A lactic acid bacterium, such as the Republic of China Invention Patent Publication No. 587098, discloses a lactic acid bacterium capable of enhancing immunity, comprising any one or more of the following biologically pure cultures stimulating an immunological concentration: Lactobacillus rhamnosus HN001 CCRC 910107; Lactobacillus brevis HN067 CCRC 910108; Bifidobacterium lactis HN019 CCRC 910110 or Lactobacillus acidophilus HN017 CCRC 910109, and a physiologically acceptable excipient or diluent, wherein the excipient or The diluent is a food product, and the food is fermented milk, yogurt, cheese, dairy drink or milk powder. Or, as disclosed in the Chinese Patent Publication No. I451871, a food composition for inhibiting an inflammatory reaction, comprising: a plurality of strains of lactic acid bacteria comprising Lactobacillus salivarius AP-32 strain, accession number BCRC 910437, road Lactobacillus reuteri TE-33 strain, accession number BCRC 910441, Lactobacillus acidophilus (Lactobacillus acidophilus) F-1 strain, accession number BCRC 910469 and Lactobacillus rhamnosus CT-53 strain, accession number BCRC 910468, wherein the lactic acid bacteria strain has gastric acid, bile salt and mold inhibitor clotrimazole (Clotrimazole) Tolerance; and a physiologically acceptable excipient or diluent, wherein the excipient or the diluent is fermented milk, yogurt, cheese, dairy powder, tea or coffee. In the above prior art, the lactic acid bacteria dosage form is a liquid or powder which is not embedded, because the lactic acid bacteria are sensitive to the pH of the environment, and the stomach acid and bile of the human body have a bactericidal effect, and the un-encapsulated lactic acid bacteria enter the human body and the bacteria body. It is easy to be destroyed, but it can not exert its proper curative effect. Secondly, due to the lack of embedding, the stability of lactic acid bacteria is insufficient, and the number of viable bacteria is easily reduced, resulting in short storage period and long-lasting survival.

In view of the above shortcomings, another lactic acid bacteria embedded in capsules, such as the Republic of China New Patent Publication No. M384660, discloses a LS66 capsule combination structure capable of inhibiting the growth of excess fat in the body, comprising a body, more than one LS66 spore lactic acid bacteria and one a coating layer, the body comprises an upper capsule and a lower capsule, and the upper capsule and the lower capsule are combined to form an accommodating space therein, and the LS66 spore lactic acid bacteria is filled in the accommodating space, and the coating layer is coated Deployed on the inner surface of the body, wherein the coating layer is an activator. However, the hard-capsule-embedded lactic acid bacteria can protect the cells from the acidic stomach environment, but the hard capsules are not easily dissolved in the intestinal tract, making the timing of releasing the cells unstable, and also having the problem of being inferior.

In addition to the above product types of liquids, powders and hard capsules, there are also crystal spheres used as materials for coating lactic acid bacteria. However, although they have the advantages of durability and resistance to stomach acid and bile, their thermal stability is not good. It takes about six hours to dissolve in the intestines, and more importantly, it is expensive.

The main purpose of the novel is to solve the problems of conventional liquid and powder lactic acid bacteria products, which are not resistant to stomach acid, bile, and lack of stability and long-lasting problems, while hard-encapsulated lactic acid bacteria are not easily dissolved in the intestine and are not durable. The problem is that the crystal ball is expensive for burying the lactic acid bacteria.

In order to achieve the above purpose, the present invention provides an embedded granule of a lactic acid bacteria embedded in a hyphae of a genus Hericium erinaceus, comprising a lactic acid sclerotium; a gelatinous substance layer coated with the lactic acid sclerotium; and a mycelium of a Hericium erinaceus shell, The layer of the gelatinous substance is coated.

As can be seen from the above, the present invention has at least the following effects compared to the prior art:

1. Using the mycelium of the Hericium erinaceus and the gelatinous substance layer as the embedding structure, the lactic acid bacteria can effectively protect the lactic acid bacteria from being affected by the surrounding environment before entering the digestive system of the living body, so that the lactic acid bacteria can smoothly reach Small intestine and large intestine.

Secondly, the lactic acid sclerotia is used to match the mycelium shell of the Hericium erinaceus. According to the results of human experiments, the embedded granule can reduce the number of Helicobacter pylori, and can effectively increase the number of lactic acid bacteria in the intestine and feces of the mouse.

3. The embedded particles have better acid resistance, bile salt resistance and pepsin resistance than conventional freeze-dried powders.

10‧‧‧Lactic acid sclerotia

11‧‧‧Lactic acid bacteria protectant

12‧‧‧Lactobacillus

20‧‧‧Colloidal layer

30‧‧‧Hymenthus fragrans

FIG. 1 is a schematic perspective view of a new embodiment of the present invention.

"Fig. 2" is a schematic view of the A-A section of Fig. 1.

The detailed description and technical content of this new model are described below with the following diagram: Please refer to FIG. 1 and FIG. 2 , which are respectively a schematic perspective view of a first embodiment of the present invention and a cross-sectional view of the AA of FIG. 1 . The present invention is a package of lactic acid bacteria embedded in the hyphae of Hericium erinaceus. The buried particles comprise a lactic acid sclerotia 10, a gelatinous substance layer 20 and a Hericium erinaceus mycelium shell 30, the gelatinous substance layer 20 coating an outer surface of the lactic acid sclerotia 10, and the Hericium erinaceus hyphae The shell layer 30 covers an outer surface of the gelatinous substance layer 20. In the embodiment, the lactic acid sclerotia 10, the gelatinous substance layer 20 and the hyphae mycelium shell layer 30 are sequentially formed from the inside to the outside. The multi-layer concentric spherical structure makes the embedded particles have a spherical shape, and the spherical shape referred to herein includes a completely spherical surface with a smooth surface and a polyhedron close to a true ball. In the present invention, the embedded particles can be prepared using a low temperature, low humidity fluid bed and drying equipment.

As shown in FIG. 2, in an embodiment of the present invention, the lactic acid bacterium 10 includes a lactic acid bacteria protecting agent 11 and a lactic acid bacteria 12 dispersed in the lactic acid bacteria protecting agent 11, and the lactic acid bacteria 12 includes a plurality of lactic acid bacteria. a powder, wherein the lactic acid bacteria protecting agent 11 may be trehalose, milk powder, polydextrose, monosodium glutamate, pyrophosphate, vitamins, arginine or a combination thereof, and the lactic acid bacteria 12 may be Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus gasseri ), Lactobacillus plantarum, Enterococcus faecium, Bifidobacterium longum, Streptococcus thermophilus, Bifidobacterium lactis, Bifidobacterium breve (Bifidobacterium breve), Bifidobacterium bifidum, Lactobacillus ferme Ntum) or a combination of the foregoing. The composition of the gelatinous substance layer 20 may be Shellac, Hydroxypropylmethylcellulose phthalate (HPMCP), Zein, Gelatin, Gum arabic, Collagen, Alginic acid sodium or a combination of the foregoing.

In summary, the novel uses the hyphae of the Hericium erinaceus and the gelatinous substance layer as an embedding structure, which can effectively protect the lactic acid bacteria from being inactive and not affected by the surrounding environment before entering the digestive system of the living body. The lactic acid bacteria can smoothly reach the small intestine and the large intestine; secondly, the lactic acid sclerotia is used to match the mycelium of the Hericium erinaceus, and according to the result of human experiment, the embedded granule can reduce the number of Helicobacter pylori, and can effectively improve the intestinal tract of the mouse And the number of lactic acid bacteria in the feces; in addition, the embedded granules have better acid resistance, bile salt resistance and pepsin resistance than the conventional lyophilized powder, and can reach the small intestine and the large intestine through the gelatinous substance layer.

The present invention has been described in detail above, but the above is only a preferred embodiment of the present invention, and the scope of the present invention is not limited. That is, the equal changes and modifications made in accordance with the scope of this new application shall remain within the scope of the patent of this new type.

10‧‧‧Lactic acid sclerotia

11‧‧‧Lactic acid bacteria protectant

12‧‧‧Lactobacillus

20‧‧‧Colloidal layer

30‧‧‧Hymenthus fragrans

Claims (8)

An embedded granule of a lactic acid bacteria embedded in a hyphae of the genus Hericium erinaceus, comprising: a lactic acid sclerotium; a gelatinous substance layer coated with the lactic acid sclerotium; and a mycelium shell of the Hericium erinaceus, covering the gelatinous substance layer . The embedding granule of the lactic acid bacteria embedded in the hyphae of the genus Hericium erinaceus according to the first aspect of the patent application, wherein the lactic acid sclerotium comprises a lactic acid bacteria protecting agent and a lactic acid bacteria dispersed in the lactic acid bacteria protecting agent. The embedding granule of the lactic acid bacteria embedded in the hyphae of the genus Hericium erinaceus according to the second aspect of the patent application, wherein the lactic acid bacteria protecting agent is selected from the group consisting of trehalose, milk powder, polydextrin, monosodium glutamate, pyrophosphate, vitamin and essence. A group of amino acids. The embedded granules of the lactic acid bacteria embedded in the hyphae of the genus Hericium erinaceus according to the second aspect of the patent application, wherein the lactic acid bacteria comprise a plurality of lactic acid bacteria powder. The embedding granules of the lactic acid bacteria embedded in the hyphae of the genus Hericium erinaceus according to the second aspect of the patent application, wherein the lactic acid bacteria are selected from Lactobacillus acidophilus, short lactic acid bacteria, Lactobacillus casei, Lactobacillus paracasei, rhamnose Lactobacillus, L. lactis, L. gasseri, Lactobacillus plantarum, Enterococcus faecium, Bifidobacterium longum, Streptococcus thermophilus, B. brevis, Bifidobacterium breve, Bifidobacterium and enzyme milk A group consisting of bacilli. The embedded particles of the lactic acid bacteria embedded in the hyphae of the genus Hericium erinaceus according to the first aspect of the patent application, wherein the composition of the gelatinous substance layer is selected from shellac, hydroxypropyl methylcellulose, zein, gelatin. , a group of gum arabic, collagen and sodium alginate. The embedded granule of the lactic acid bacteria embedded in the hyphae of the genus Hericium erinaceus according to the first aspect of the patent application, wherein the lactic acid sclerotium, the gelatinous substance layer and the hyphae of the Hericium erinaceus are sequentially formed from the inside to the outside. Multi-layer concentric ball structure. The embedded particles of the lactic acid bacteria embedded in the hyphae of the genus Hericium erinaceus according to the first aspect of the patent application are in the form of a sphere.